Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

CHEMBL68649 N-[(2S,6R,9aR)-6-methyl- 2,3,4,6,7,8,9,9a...

Synonyms: BMY-27709, AC1L2RSV, AC1Q3LRY, DNC000334, AR-1G0710, ...

Luo, G. et al., Luo, G. et al., Combrink, K.D. et al.

Luo, Colonno, Krystal, Combrink, Gulgeze, Yu, Pearce, Trehan, Wei, Deshpande, Krystal, Torri, Luo, Cianci, Danetz, Tiley, Meanwell, Luo, Torri, Harte, Danetz, Cianci, Tiley, Day, Mullaney, Yu, Ouellet, Dextraze, Meanwell, Colonno, Krystal,

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Brl 20627

Recently, we identified and characterized BMY-27709 as an inhibitor of the H1 and H2 subtypes of influenza A virus that specifically inhibits the HA function necessary for virus-cell membrane fusion (G.-X. Luo, R. Colonno, and M. Krystal, Virology 226:66-76, 1996) [1].
This was confirmed through the use of reassortant viruses and the isolation of a virus resistant to BMY-27709 [2].
BMY-27709 is able to inhibit virus-induced red blood cell hemolysis, suggesting that it blocks the membrane fusion function of hemagglutinin [2].

High impact information on Brl 20627

This compound (BMY-27709) has an IC50 of 3-8 microM for A/WSN/33 virus growth in a multicycle replication assay and is active against all H1 and H2 subtype viruses tested [2].
That this single mutation was responsible for the acquisition of resistance to BMY-27709 was proven through reverse genetics, as transfectant virus containing only this change was shown to be resistant to BMY-27709, while the control virus without this mutation remained sensitive [2].

Analytical, diagnostic and therapeutic context of Brl 20627

Structural variation of the quinolizidine heterocycle of the influenza fusion inhibitor BMY-27709 was examined by several topological dissections in order to illuminate the critical features of the ring system [3].

References

Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virus. Luo, G., Torri, A., Harte, W.E., Danetz, S., Cianci, C., Tiley, L., Day, S., Mullaney, D., Yu, K.L., Ouellet, C., Dextraze, P., Meanwell, N., Colonno, R., Krystal, M. J. Virol. (1997) [Pubmed]
Characterization of a hemagglutinin-specific inhibitor of influenza A virus. Luo, G., Colonno, R., Krystal, M. Virology (1996) [Pubmed]
Salicylamide inhibitors of influenza virus fusion. Combrink, K.D., Gulgeze, H.B., Yu, K.L., Pearce, B.C., Trehan, A.K., Wei, J., Deshpande, M., Krystal, M., Torri, A., Luo, G., Cianci, C., Danetz, S., Tiley, L., Meanwell, N.A. Bioorg. Med. Chem. Lett. (2000) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.